ArticleBMC public health2016
Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.
Article in BMC public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis.BMJ global health · 2020Pooled it
- Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.BMC infectious diseases · 2017Pooled it
- Magnitude of multidrug resistant Mycobacterium tuberculosis and associated risk factors among pulmonary tuberculosis patients in Tigray region, Ethiopia.BMC infectious diseases · 2026Article
- Association of D516V, H526Y, and S531L rpoB gene polymorphisms and risk factors with rifampicin resistance in Mycobacterium tuberculosis isolates from pulmonary TB patients in Northwest Amhara, Ethiopia: cross-sectional study.BMC infectious diseases · 2025Article
- Drug-resistant tuberculosis profiles among patients presenting at the antituberculosis center of Brazzaville, Republic of Congo.Annals of clinical microbiology and antimicrobials · 2025Article
- Prevalence and Determinants of Drug-Resistant Tuberculosis (DR-TB) Among Tuberculosis Patients in Pokhara Metropolitan City, Gandaki Province, Nepal.Interdisciplinary perspectives on infectious diseases · 2025Article
- Spiritual Holy Water Sites in Ethiopia: Unrecognized High-Risk Settings for Transmission of Pulmonary Tuberculosis.International journal of microbiology · 2024Article
- Pulmonary tuberculosis case notification and burden of drug resistance among children under 15 years of age in Ethiopia: sub-analysis from third-round drug resistance tuberculosis survey.BMC pediatrics · 2023Article
- Risk-adjusted active tuberculosis case finding strategy in central Ethiopia.IJID regions · 2022Article
- The prevalence of Mycobacterium tuberculosis using Gene Xpert among tuberculosis suspected patients in Gedeo Zone, Southern Ethiopia.European journal of medical research · 2022Article
- Analysis of the application of a gene chip method for detecting Mycobacterium tuberculosis drug resistance in clinical specimens: a retrospective study.Scientific reports · 2021Article
- Prevalence of Mycobacterium tuberculosis (Rifampicin-Resistant MTB) and Associated Risk Actors Among Pulmonary Presumptive TB Patients in Eastern Amhara, Ethiopia: 2015-2019.Infectious diseases and therapy · 2021Article
- Whole Genome Sequencing of Drug Resistant and Drug SusceptibleFrontiers in microbiology · 2021Article
- The Magnitude of MTB and Rifampicin Resistance MTB Using Xpert-MTB/RIF Assay Among Tuberculosis Suspected Patients in Gedeo Zone, Southern Ethiopia.Infection and drug resistance · 2021Article
- Rifampicin-ResistantInfection and drug resistance · 2020Article
- Article
- Determinants of Drug-Resistant Tuberculosis in Southern Ethiopia: A Case-Control Study.Infection and drug resistance · 2020Article
- Molecular characterization of pre-extensive drug resistant Mycobacterium tuberculosis in Northeast Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2020Article
- Spoligotyping and drug sensitivity ofNew microbes and new infections · 2020Article
- Rifampicin-resistantInfection and drug resistance · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant tuberculosis (MDR-TB) drugs which is resistant to the major first-line anti-TB drugs, Isoniazid and Rifampicin, has become a major global challenge in tuberculosis (TB) control programme. However, its burden at community level is not well known. Thus, the aim of study was to assess the prevalence of primary and secondary resistance to any first line anti-TB drugs and MDR TB in Hitossa District of Oromia Regional State, Central Ethiopia.
methodsPopulation based cross- sectional study was conducted on individuals aged ≥15 years. Those with symptoms suggestive of TB were interviewed and two sputum specimens were collected from each and examined using Lowenstein-Jensen (LJ) culture medium. Further, the isolates were confirmed by the Ziehl-Neelsen microscopic examination method. Drug susceptibility test (DST) was also conducted on LJ medium using a simplified indirect proportion method. The resistance strains were then determined by percentage of colonies that grew on the critical concentration of Isoniazid, Streptomycin, Rifampicin and Ethambutol.
resultsThe overall resistance of all forms of TB to any first-line anti-TB drug was 21.7 %. Of the total new and previously treated culture positive TB cases, 15.3 and 48.8 % respectively were found to be a resistant to any of the first-line anti-TB drugs. Further, of all forms of TB, the overall resistance of MDR-TB was 4.7 %. However, of the total new TB cases, 2.4 % had primary while 14.3 % had secondary MDR-TB. Resistance to any of the first-line anti-TB drugs (adjusted odd ratio (AOR), 8.1; 95 % CI: 2.26-29.30) and MDR-TB (AOR), 7.1; 95 % CI: 2.6-43.8) was found to be linked with previous history of anti-TB treatment.
conclusionsThe study has identified a high rate of primary and secondary resistance to any of the first-line anti-TB drugs and MDR-TB in the study area. The resistance may have resulted from sub-optimal performance of directly observed treatment short-course (DOTS) programme in the detecting infectious TB cases and cure rates in the study area. Anti-TB drug resistance is linked with previous TB treatment. There is a need to strengthen DOTS and DOTS-Plus programmes and expand MDR-TB diagnostic facilities in order to timely diagnose MDR-TB cases and provide appropriate treatment to prevent the spread of MDR-TB in Ethiopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.